Clinical Trial Update: Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating vorinostat to prevent graft-versus-host disease in children, adolescents, and young adults undergoing allogeneic hemato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Hematologic Diseases, Acute Leukemia in Remission | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING